InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Kiniksa Pharmaceuticals International, plc

KNSA Clue Score67
Fiscal year ends December CIK 0001730430
$79.78 +1.31% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $79.78 +600.44% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 24 May 2018. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back. P/E and P/FCF are the market value over the last full fiscal year's net income or free cash flow, as public on each day, so they step once a year when the annual report comes out. A hatched band marks a stretch with none: a year of net loss, or of cash burnt.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2017Operating income−65.4Net income−64.9Fiscal year 2018Operating income−108.2Net income−103.2Fiscal year 2019Operating income−170.0Net income−161.9EPS, diluted−2.99Fiscal year 2020Operating income−157.4Net income−161.4EPS, diluted−2.61Fiscal year 2021Revenue38.5Operating income−156.6Net income−157.9EPS, diluted−2.30Fiscal year 2022Revenue220.2 +471.2%Operating income9.8Net income183.4EPS, diluted2.60Fiscal year 2023Revenue270.3 +22.7%Operating income−25.2Net income14.1 −92.3%EPS, diluted0.20 −92.3%Fiscal year 2024Revenue423.2 +56.6%Operating income−45.6Net income−43.2 −406.7%EPS, diluted−0.60 −400.0%Fiscal year 2025Revenue677.6 +60.1%Operating income77.2Net income59.0EPS, diluted0.75
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue n/a n/a n/a n/a 38.5 220.2 270.3 423.2 677.6
Growth +471.2% +22.7% +56.6% +60.1%
Operating income −65.4 −108.2 −170.0 −157.4 −156.6 9.8 −25.2 −45.6 77.2
Net income −64.9 −103.2 −161.9 −161.4 −157.9 183.4 14.1 −43.2 59.0
Growth −92.3% −406.7%
EPS, diluted n/a n/a −2.99 −2.61 −2.30 2.60 0.20 −0.60 0.75
Growth −92.3% −400.0%

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2017Fiscal year 2018Fiscal year 2019Fiscal year 2020Fiscal year 2021Operating margin−406.4%Net margin−409.7%Free cash flow margin−328.7%Fiscal year 2022Operating margin4.4%Net margin83.3%Free cash flow margin2.6%Fiscal year 2023Operating margin−9.3%Net margin5.2%Free cash flow margin4.9%Fiscal year 2024Operating margin−10.8%Net margin−10.2%Free cash flow margin6.0%Fiscal year 2025Operating margin11.4%Net margin8.7%Free cash flow margin20.1%
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating margin n/a n/a n/a n/a −406.4% 4.4% −9.3% −10.8% 11.4%
Net margin n/a n/a n/a n/a −409.7% 83.3% 5.2% −10.2% 8.7%
Free cash flow margin n/a n/a n/a n/a −328.7% 2.6% 4.9% 6.0% 20.1%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2017Operating cash flow−50.2Capital expenditure−0.1Free cash flow−50.3Dividends paid0.0Fiscal year 2018Operating cash flow−81.0Capital expenditure−5.3Free cash flow−86.3Dividends paid0.0Fiscal year 2019Operating cash flow−158.4Capital expenditure−3.2Free cash flow−161.6Fiscal year 2020Operating cash flow−136.5Capital expenditure−0.3Free cash flow−136.8Fiscal year 2021Operating cash flow−126.3Capital expenditure−0.4Free cash flow−126.7Fiscal year 2022Operating cash flow5.8Capital expenditure−0.1Free cash flow5.7Fiscal year 2023Operating cash flow13.3Capital expenditure−0.1Free cash flow13.2 +131.0%Fiscal year 2024Operating cash flow25.7Capital expenditure−0.3Free cash flow25.4 +92.9%Fiscal year 2025Operating cash flow138.0Capital expenditure−1.6Free cash flow136.4 +436.8%
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −50.2 −81.0 −158.4 −136.5 −126.3 5.8 13.3 25.7 138.0
Capital expenditure −0.1 −5.3 −3.2 −0.3 −0.4 −0.1 −0.1 −0.3 −1.6
Free cash flow −50.3 −86.3 −161.6 −136.8 −126.7 5.7 13.2 25.4 136.4
Growth +131.0% +92.9% +436.8%
Dividends paid 0.0 0.0 n/a n/a n/a n/a n/a n/a n/a

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2017Cash45.6Shareholders’ equity−89.7Fiscal year 2018Cash72.0Shareholders’ equity279.3Fiscal year 2019Cash46.9Shareholders’ equity225.4Fiscal year 2020Cash114.0Shareholders’ equity311.9Fiscal year 2021Cash122.5Shareholders’ equity185.0Fiscal year 2022Cash122.7Shareholders’ equity396.1Fiscal year 2023Cash108.0Shareholders’ equity438.8Fiscal year 2024Cash183.6Shareholders’ equity438.4Fiscal year 2025Cash165.6Shareholders’ equity567.6
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash 45.6 72.0 46.9 114.0 122.5 122.7 108.0 183.6 165.6
Shareholders’ equity −89.7 279.3 225.4 311.9 185.0 396.1 438.8 438.4 567.6

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2017 31 Dec 2017 FY2018 31 Dec 2018 FY2019 31 Dec 2019 FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Revenue and profit
n/a n/a n/a n/a 38.5 220.2 270.3 423.2 677.6
Growth +471.2% +22.7% +56.6% +60.1%
n/a n/a n/a n/a 9.1 22.9 33.4 60.9 77.7
56.4 86.6 135.0 112.0 99.3 65.5 76.1 111.6 96.9
9.0 21.6 35.0 45.3 85.9 98.0 129.4 168.0 196.3
−65.4 −108.2 −170.0 −157.4 −156.6 9.8 −25.2 −45.6 77.2
Growth −357.8%
−64.9 −103.4 −163.9 −156.2 −156.5 11.0 −16.7 −36.2 88.9
0.0 −0.2 −2.0 5.2 1.4 −172.3 −30.7 7.0 29.9
−64.9 −103.2 −161.9 −161.4 −157.9 183.4 14.1 −43.2 59.0
Growth −92.3% −406.7%
Per share
n/a n/a −2.99 −2.61 −2.30 2.64 0.20 −0.60 0.80
n/a n/a −2.99 −2.61 −2.30 2.60 0.20 −0.60 0.75
Growth −92.3% −400.0%
n/a n/a 54.0 61.8 68.6 69.4 70.1 71.4 74.2
n/a n/a 54.0 61.8 68.6 70.4 71.9 71.4 79.0
Growth +14.4% +10.9% +2.7% +2.1% −0.7% +10.6%

Five years in brief

Worked out from the figures above, not from a press release
  • The diluted share count rose 27.7% in five years, which is dilution.
  • A net loss in 6 of 9 years on file.